After hours: 7:59:47 pm GMT-5 ...
Developed by Johnson & Johnson, guselkumab (GUS) is the first approved fully-human, dual-acting IL-23p19 subunit inhibitor that blocks IL-23 and binds to CD64, a receptor on cells that produce IL-23.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback